Navigation Links
Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference
Date:9/3/2014

SAN DIEGO, Sept. 3, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Morgan Stanley Global Healthcare Conference in New York City.  

The live presentation takes place on Wednesday, September 10 at 11:30am ET (8:30am PT).  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.  

Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month.

Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders. The Company's two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc., and a wholly owned vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders. Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company.  Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Neurocrine Biosciences Reports Second Quarter 2014 Results
2. Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results
3. Neurocrine Announces 12-Week Safety Results From Initial Phase IIB Study Of VMAT2 Inhibitor NBI-98854
4. Healthcare Companies Report Conference Presentation Schedule, Stock Price Updates, and Clinical Study Results - Research Report on Medivation, Envision Healthcare, Fonar, Idera Pharma, and Neurocrine
5. Neurocrine Announces Positive Results of VMAT2 Inhibitor NBI-98854 in Kinect 2 Study
6. Neurocrine Biosciences To Present At Oppenheimers 24th Annual Healthcare Conference
7. Neurocrine Biosciences Announces Conference Call And Webcast To Present Third Quarter 2013 Financial Results
8. Clinical Trial Results, Litigation Outcomes and Marketing Authorizations - Research Report on Pfizer, GlaxoSmithKline, Sanofi, AstraZeneca, and Neurocrine
9. Neurocrine Announces Phase IIb Results Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia
10. Clinical Trials, New Orders, Improved Services, and Approvals - Research Report on CareFusion, St. Jude Medical, Community Health Systems, Neurocrine Biosciences, and Alnylam Pharmaceuticals
11. Neurocrine Biosciences Announces the Start of Second Phase III Study of Elagolix in Endometriosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... , Jan. 20, 2017  Faruqi & Faruqi, LLP, ... Inc. ("KemPharm" or the "Company") (NASDAQ: KMPH ) ... Company and certain officers and directors and underwriters of the ... seek the role of lead plaintiff. The lawsuit ... District Court for Johnson County on ...
(Date:1/20/2017)... , Jan 20, 2017 Research ... Stability Testing Market Trends, Opportunities, and Future" report to their ... This ... sizing, emerging trends, and technologies, and provides a snapshot of the ... is 2015 and forecasts are provided from 2016 to 2020. The ...
(Date:1/19/2017)... Germany Cataract Surgery Devices ... report, "Germany Cataract Surgery Devices Market Outlook to 2022", ... Devices market. The report provides value, in millions of ... within market segements - Phacoemulsification Equipment and Ophthalmic Viscoelastic ... and distribution shares data for each of these market ...
Breaking Medicine Technology:
(Date:1/21/2017)... ... , ... In the United States, 20 million women and 10 million men ... feel shame for having struggled with an eating disorder as well as common co-occurring ... in Life After an Eating Disorder” -- to be featured at this year’s iaedp ...
(Date:1/20/2017)... ... ... Aquatics Launches New ADA Portable Motion Trek BP 300 Lift. Built for durability, this pool ... it can be wheeled out of the way and stored when not in use. It ... transformed the feedback from customers into specific enhancements and created a new product that is ...
(Date:1/20/2017)... Texas (PRWEB) , ... January 20, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at ... the bible in homes across the world. Yisrayl says this generation is a time like ... is to turn to the Bible. , Yisrayl says he does not want to sound ...
(Date:1/20/2017)... ... , ... Doctor C LLC, a company based out of Arizona that focuses ... the marketing and distribution of its product, The Right C. , The Right C ... than traditional vitamin C supplements. At the trade show, Doctor C had the opportunity ...
(Date:1/20/2017)... , ... January 20, 2017 , ... Lice Troopers, the ... cases in families with school-aged children since the holiday season. , “It happens ... with their families, sharing hugs and taking photos, which is the head-to-head gateway that ...
Breaking Medicine News(10 mins):